A chemokine binding assay on whole cells was developed using biotinylated synthetic CCL22 as a model ligand. CCL22 analogues were produced by a chemical route, resulting in > 97% homogeneous and defined polypeptides. First, the 5 biotinylated CCL22 analogues synthesized were captured by agarose-immobilized streptavidin, indicating that the biotin molecules introduced in positions G1, K27, K49, K61, and K66 of CCL22 were accessible for binding. Then, it was established using a migration assay that the biotinylated chemokines were at least as biologically active as the unmodified CCL22 form. Subsequently, the biotinylated chemokines were evaluated in an FACS-based whole-cell binding assay. Surprisingly, only the CCL22 analogue with the biotin in position K66 constituted a suitable staining reagent for CCR4-positive cells. Finally, binding characteristics and reproducibility of the binding assay were outlined for the CCL22 analogue with the biotin in position K66. These results exemplified that biotinylated synthetic chemokines constitute promising ligands for the development of chemokine receptor-binding assays on whole cells, provided the position of the biotin moiety introduced along the sequence is adequately chosen. (Journal of Biomolecular Screening 2003:316-323) 
INTRODUCTION
O VER THE PAST FEW YEARS, the biology of chemokines has been the subject of intense research activities. In a short time span, many chemokines and their corresponding receptors were identified. With the sequencing of the human genome and the advent of its computer-based analysis, several chemokines were indeed first identified through their gene, rather than by isolation of the protein itself. It was soon realized that chemokines are involved in many physiological processes, such as cell migration, cell activation, and angiogenesis, but are also implicated in pathological manifestations, such as inflammation and AIDS. 1, 2 This situation has prompted the pharmaceutical sector to attempt the isolation of low molecular weight compounds capable of interfering with the interaction between chemokines and their receptors. [3] [4] [5] Obviously, the success of this undertaking meant relying on the availability of binding tests that would be suitable for high-throughput screening. Initially, binding assays were developed with the use of radiolabeled chemokines, but this approach is no longer a preferred option due to the multiple problems associated with radioactive material handling. Alternative approaches were contemplated, among them the use of haptens, such as biotin, for the tagging of chemokines. [6] [7] [8] The problem encountered at that stage is introducing the hapten without interfering with the biological activity of the chemokines, particularly the binding characteristics to their receptors. One approach relied on the modification of recombinant chemokine using chemically activated biotin forms. Even though straightforward, the major flaw of this method is the difficulty in controlling how much and where on the peptide the biotin moieties are introduced. As a result, the chemokines had a markedly decreased biological activity as compared with the unmodified one. 9 Alternatively, some investigators pursued an enzymatic approach of chemokine modification. 10 Albeit ingenuous, this method is labor intensive, and the tagged chemokine is obtained in low yield. In particular, it requires the difficult separation of the labeled from the unlabeled chemokine. In addition, if successful for some chemokines, this method is by no means applicable to all peptide ligands, and is also limited by the availability and suitability of the substrates.
CCL22, also called macrophage-derived chemokine (MDC), is one of the ligands of the chemokine receptor CCR4. It is now well documented that T lymphocytes expressing CCR4 play a critical role in the pathogenesis of allergic inflammation. Therefore, CCR4 constitutes an attractive target for the pharmacological treatment of allergic manifestations. 11, 12 Here, we describe the production of 5 biotinylated CCL22 analogues and the use of one of them for the development of a whole-cell binding assay. These results illustrate the advantage of the chemical synthesis approach over recombinant protein expression methods for the production of tagged polypeptide ligands retaining unaltered receptor-binding capacity and full biological activity.
MATERIALS AND METHODS

Peptide synthesis, purification, and folding
Synthetic human CCL22 was assembled using Fmoc chemistry as described. 13 Biotin was introduced during synthesis under the form of biotinylated Fmoc-protected lysine residues (in positions K27, K49, K61, or K66) or by modification of the N-terminal residue (G1) with a 10-fold molar excess of biotin N-succinimidyl ester (Fluka, Buchs, Switzerland) dissolved in 54% dimethylformamide, 46% n-methylpyrrolidone, and 150 mM diisopropylethylamine for 3 h at room temperature. Following trifluoroacetic cleavage from the resin, the crude polypeptide was fractionated by reverse-phase high-pressure liquid chromatography (RP-HPLC) and lyophilized as described. 13 Then, it was solubilized in 3 M guanidium • HCl, 50 mM Na 2 HPO 4 , and 5 mM Tris (pH 8.0) in the presence of a 100-fold molar excess of cysteine over peptide. After 1 day of incubation at 37°C, oxidation was stopped by the addition of trifluoroacetic acid to a final concentration of 0.2%, and the chemokine was isolated by RP-HPLC. Purity and identity of the chemokine were finally assessed by RP-HPLC and mass spectrometry (MS) analysis.
Streptavidin-agarose capture
Samples of chemokines (25 µg in 175 µL phosphate buffer saline) were incubated for 1 h at room temperature under continuous agitation in the presence or the absence of 50 µL of streptavidinagarose (Sigma, St. Louis, MO). Then, the resin was discarded and the samples analyzed by RP-HPLC.
Cell culture
CCR4-transfected B lymphoma cells were obtained as described 14 and cultured in RPMI 1640 medium supplemented with glutamine, nonessential amino acids, sodium pyruvate, kanamycine, 5 × 10 -5 M 2-mercaptoethanol (all from InVitrogen, Basel, Switzerland), 10% fetal calf serum (FCS), and 1.5 µg/mL puromycin (Sigma).
Migration assay
Migration induced by the CCL22 analogues was determined using 5 µm polycarbonate Transwell inserts (Costar, Corning, NY). Briefly, 3 × 10 5 cells in 100 µL RPMI 1640 and 0.5% bovine serum albumin were dispensed into the upper chambers of the migration wells. Chemokine in the same medium was added to the lower chambers in a final volume of 600 µL. After 3 h incubation at 37°C, cell migration was determined using a lactate dehydrogenase assay-based colorimetric assay (CytoTox 96 nonradioactive cytotoxicity assay, Promega, Madison, WI) on the cells recovered in the lower chambers. Results are given as means of duplicate determinations of the optical density (OD) at 490 nm.
Flow cytometry
CCR4-transfected or untransfected B300.19 mouse lymphoma cells were incubated in staining buffer made of phosphate buffer saline (PBS) and 5% AB serum for 30 min at 4°C in the presence or the absence of 1 µg/mL biotinylated antihuman CCR4 monoclonal antibody (mAb, 1G1.1, BD Biosciences, San Jose, CA). The cells were then washed with staining buffer and incubated with 100 ng/mL phycoerythrin (PE)-conjugated streptavidin (Biosource International, Nivelles, Belgium) for 30 min at 4°C. After 2 washings with staining buffer, the cells were fixed in PBS with 1% FCS and 1% paraformaldehyde. Cell analysis was performed on a FACSCalibur cytofluorometer (BD Biosciences).
For staining using biotinylated chemokine, 3 × 10 5 CCR4transfected or untransfected B300.19 cells were incubated with biotinylated CCL22 at the indicated concentrations for 1 h at 4°C, followed by incubation with a fluorescein-isothiocyanate (FITC)conjugated avidin (BD Biosciences) at 2.5 µg/mL (FITC-avidin). Alternatively, staining was performed by addition to T cells of preformed complexes between biotinylated CCL22(K66) and FITCavidin used at 300 ng/mL and 2.5 µg/mL, respectively. After 2 repetitive washings with PBS, cells were fixed in PBS with 1% FCS and 1% paraformaldehyde before fluorescence-activated cell sorting (FACS) analysis.
RESULTS
Production and chemical characterization of 5 biotinylated CCL22 analogues
The CCL22 sequence was assembled using solid-phase Fmoc chemistry. The N-terminal glycine residue and the lysine residues 27, 49, 61, and 66 were singly modified with a biotin moiety. Following synthesis, the peptides were cleaved from the resin, RP-HPLC purified, and oxidized. After final RP-HPLC purification, homogeneity and identity of the chemokine species were assessed. Analytical RP-HPLC showed that each of the different chemokine species eluted as a single, symmetrical peak, indicating a purity > 97%. MS analysis established that the synthetic material contained 1 molecular species of the expected molecular mass. The example of CCL22 biotinylated in position K66, named biotinylated CCL22(K66), is depicted in Figure 1 . Similar profiles were obtained with the unmodified CCL22 molecule and the other biotinylated CCL22 analogues (data not shown).
Capture of the 5 biotinylated CCL22 analogues by streptavidin-agarose
To assess whether the biotin moiety introduced in the different positions along the sequence of CCL22 was accessible for binding, samples of the 5 biotinylated CCL22 analogues, as well as the unmodified form, were incubated in the presence or the absence of streptavidin-agarose. Subsequently, the amount of chemokine left in the samples was evaluated by RP-HPLC. For the 5 biotinylated CCL22 species tested, incubation with streptavidin-agarose resulted in the complete disappearance of the chemokine. When no preincubation with streptavidin-agarose was applied, the 5 chemokine species eluted as single peaks. The example of biotinylated CCL22(K66) is presented ( Fig. 2A,B ). By contrast, the unmodified CCL22 form was not bound by streptavidin- agarose (Fig. 2C,D) . Together, these results indicated that for the 5 biotinylated CCL22 analogues, the biotin moiety was accessible for binding by streptavidin.
Unaltered biological activity of the 5 biotinylated CCL22 analogues
First, it was shown that CCL22 induced migration of CCR4transfected cells. Although the extent of migration was low at 0.1 ng/mL, it increased together with CCL22 concentration and reached a maximum at 10 ng/mL. At higher concentrations of CCL22, extent of migration decreased. By contrast, untransfected cells did not migrate at all over the whole range of CCL22 concentrations tested (Fig. 3 ). These results indicated that the migration of the CCR4-transfected cells was indeed promoted by the CCL22 and CCR4 interaction. Then, the 5 biotinylated CCL22 analogues were evaluated for their capacity to induce migration of CCR4transfected cells. Similar to the bell-shaped dose-response curve observed with unmodified CCL22, the 5 biotinylated CCL22 analogues promoted maximal migration at a dose of 1 to 10 ng/mL and low migration still detectable at 0.1 ng/mL ( Fig. 4 ). More specifically, two analogues, CCL22(K27) and CCL22(K66), induced maximal migration at 1 ng/mL, whereas for the other 3 analogues and for the unmodified form of CCL22, the optimal concentration was 10 ng/mL ( Fig. 4 ). It is not yet known whether these differences in biological activities were due to distinct structural alterations between the CCL22 analogues or were within the experimental variations of the assay. Altogether, these results showed that the biotin molecule introduced in the 5 positions evaluated did not significantly impair the biological activity of the chemokine because the corresponding biotinylated CCL22 analogues were found at least as active as the unmodified CCL22 species. It there-fore suggested that the characteristics of binding between CCL22 and CCR4 were maintained overall by the introduction of a biotin molecule in these 5 different positions.
CCL22 biotinylated in position K66 as a reagent for a whole-cell binding assay
It was then attempted to detect binding of the biotinylated CCL22 species on whole cells expressing CCR4. Staining of CCR4-transfected cells using a biotinylated anti-CCR4 mAb and PE-labeled streptavidin as a secondary reagent revealed the presence of CCR4 on these cells (Fig. 5A) . By contrast, no CCR4 expression was detected on the untransfected cells ( Fig. 5B ). Specificity of CCR4 detection was further established by the observation that no staining of CCR4-transfected and untransfected cells was obtained with an isotype-matched IgG of irrelevant antigen specificity ( Fig. 5C,D) . Then, binding of biotinylated CCL22(K66) on the CCR4-positive cells was studied. Presence of bound chemokine was revealed by the addition of FITC-avidin. A staining as intense as the one obtained with biotinylated anti-CCR4 mAb was observed following incubation of CCR4-transfected cells with biotinylated CCL22(K66) (Fig. 5E ). By contrast, no staining of untransfected cells was detected (Fig. 5F ). These results indicated that the staining was due to the binding of biotinylated CCL22(K66) to CCR4. The 4 other biotinylated analogues were also evaluated for their ability to work as FACS staining reagents. Surprisingly, only the biotinylated CCL22(K66) analogue resulted in intense staining of CCR4-positive cells. By contrast, the biotinylated CCL22(K27) analogue was faintly detected, and the biotinylated CCL22(G1), CCL22(K49), and CCL22(K61) analogues did not result in staining of CCR4-transfected cells ( Table 1 , experiment 1). Because the biotinylated CCL22(K66) analogue was found to be the only suitable staining reagent, its binding characteristics were further delineated. First, its binding was shown to be impeded by preincubation of CCR4-transfected cells with increasing concentrations of unmodified CCL22 (Table 1 , experiment 2). These results established the saturable nature of the CCL22 receptor expressed on these cells and ruled out that the binding to CCR4 was due to the biotin moiety. The sensitivity of the staining was then evaluated. Weak staining was detected with concentrations of biotinylated CCL22(K66) analogue as low as 10 ng/mL. Staining intensity reached a plateau at 300 ng/mL of biotinylated CCL22(K66) analogue ( Table 1 , experiment 3). Because 300 ng/ mL corresponded to a concentration eliciting maximal migration of CCR4-transfected cells, it indicated that cell staining represented a relevant correlate for migration. It was subsequently assessed whether the staining procedure could be made easier by preforming complexes between the biotinylated CCL22(K66) analogue and FITC-avidin prior to addition to cells. It was expected that this simplified procedure would increase throughput of samples in this staining assay. It was found that when made at a 1:1 molar ratio, biotinylated CCL22(K66) analogue and FITC-avidin complexes resulted in whole-cell staining ( Table 1 , experiment 4). By contrast, when the biotinylated CCL22(K66) analogue and FITC-avidin were preincubated at a molar ratio lower or higher than 1, no staining of CCR4-transfected cells was obtained (data not shown).
Biotinylated Synthetic Chemokines
Finally, the reproducibility of this biotinylated CCL22(K66)based whole-cell binding assay was assessed by performing a 24replicate staining of untransfected and CCR4-transfected cells using optimal concentrations of biotinylated CCL22(K66) (300 ng/ mL) and FITC-avidin (2.5 µg/mL). Mean fluorescence intensity of untransfected and CCR4-transfected cells was 3.76 ± 0.03 and 6.11 ± 0.24, respectively (Fig. 6) . These results documented that this assay had a low intrinsic variability and therefore could be suitable for screening applications.
DISCUSSION
This work was aimed at the development of a nonradioactive whole-cell chemokine binding assay. Using an FACS-based detection system, binding between CCR4 and CCL22 using a biotinylated form of CCL22 was visualized with a fluorescence intensity equivalent to the one obtained with a biotinylated anti-CCR4 mAb. This finding was not anticipated, considering the high biotin content of the mAb (5-10 biotin/mAb) as compared with the synthetic chemokine (1 biotin/chemokine). Surprisingly, only 1 biotinylated CCL22 analogue, out of the 5 tested, constituted a suitable reagent for CCR4 staining on whole cells. Initially, it was by using the RasMol molecular graphics visualization program (www.rasmol.org) that positions along the sequence were chosen. The biotin moieties displayed by the residues selected were predicted to point toward the solvent and therefore to be accessible for Thierry et al. MFI, mean fluorescence intensity. In experiment 1, G1 (N-terminal), K27, K49, K61, and K66 refer to the different CCL22 analogues, biotinylated at the corresponding residues along the sequence. The analogues were tested at 300 ng/mL and revealed with 2.5 µg/mL fluorescein-isothiocyanate (FITC)-avidin. In experiment 2, CCR4-transfected cells were preincubated with increasing concentrations of unlabeled CCL22, followed by the sequential addition of 100 ng/mL biotinylated CCL22(K66) and 2.5 µg/mL FITC-avidin. In experiment 3, CCR4-transfected cells were incubated with increasing concentrations of biotinylated CCL22(K66), followed by the addition of 2.5 µg/mL FITC-avidin. In experiment 4, untransfected and CCR4-transfected cells were incubated either with biotinylated CCL22(K66) at 300 ng/mL, followed by the addition of FITC-avidin at 2.5 µg/mL (2 steps), or with preformed complexes between biotinylated CCL22(K66) and FITC-avidin at 300 ng/mL and 2.5 µg/mL, respectively (complexes).
binding by a capture protein, such as streptavidin. This assumption was indeed confirmed by the fact that streptavidin-agarose was found to efficiently bind the 5 biotinylated CCL22 analogues. In addition, because the 5 CCL22 analogues were at least as active in migration assays as the unmodified CCL22 molecule, one may predict that these different CCL22 species did indeed bind to CCR4. Work from other investigators identified patches of residues on the chemokine, which are needed for binding to the receptor. 15, 16 On the basis of the structure similarities between chemokine species, one may estimate that the residues used for biotinylation are not the ones directly in contact with CCR4. This is indeed likely because the biotinylated CCL22 analogues were found to exhibit full biological activity. In this respect, it came as a surprise that the analogue biotinylated in the N-terminal residue showed an unaltered capacity of inducing migration of CCR4transfected cells. A possibility is that the biotin moiety did not interfere with CCR4 binding. Alternatively, the N-terminal glycine residue might be cleaved during the cell-binding assay, resulting in a ligand still capable of binding to its receptor. However, the reported cleavage of the N-terminal dipeptide was shown to generate an inactive truncated CCL22 analogue. 17, 18 It remains that the failure of detecting some of the biotinylated CCL22 analogues in an Reproducibility of whole-cell staining assay using biotinylated CCL22(K66). Twenty-four samples of 10 5 CCR4-transfected cells and untransfected cells were sequentially incubated with 300 ng/mL biotinylated CCL22(K66) followed by 2.5 µg/mL fluoresceinisothiocyanate (FITC)-avidin. Mean fluorescence intensity was then determined by fluorescence-activated cell sorting (FACS). Mean fluorescence intensity of untransfected and CCR4-transfected cells was 3.76 ± 0.03 and 6.11 ± 0.24, respectively. FACS-based assay was likely due to accessibility constraints for the detecting reagent FITC-avidin. Similar results were obtained in a microscopy-based application (FMAT, Applied Biosystems, personal communication, 2002). Intriguingly, other secondary reagents than FITC-avidin, such as FITC-streptavidin, PEstreptavidin, or Alexa Fluor 488-labeled antibiotin mAb, failed to detect biotinylated CCL22(K66) bound onto CCR4 positive cells (unpublished results). These negative results might be related to the size of the detecting reagents, which prevented access to the biotin molecules. Until experimentally tested, it is still a possibility that other residues than those evaluated here could constitute biotinylation sites accessible to alternative secondary reagents. It is not yet established whether a similar situation would be found in the case of other chemokines. Considering the high sequence and structure homologies between chemokines, one may hypothesize that for other chemokines, only a restricted number of residues would also constitute adequate biotinylation sites for the development of staining reagents suitable for whole-cell binding assays.
The findings reported here are not limited to CCL22 because similar results were recently obtained for a biotinylated CCL2 form and CCR2 and for a biotinylated CCL19 form and CCR7 (unpublished results). However, binding of other biotinylated chemokines to their corresponding receptors, such as CCL1 to CCR8, CCL5 to CCR5, and CCL11 to CCR3, was found to be considerably weaker, if not absent, even though receptor expression was high and the concentration of chemokine needed to elicit migration was low, as in the cases for which binding was detected. The inability to detect binding could be explained by the fact that the biotin was not positioned adequately on these analogues. Alternatively, the binding characteristics of these chemokines could be different from the ones successfully detected. For instance, in the case of chemokines with rapid off-rates, leaving the unbound chemokine in the presence of its receptor could prevent displacement of the equilibrium toward the unbound species. Preliminary experiments indeed indicated that the binding conditions (e.g., temperature) play a critical role for the detection of biotinylated chemokines on whole cells (unpublished results).
A clear advantage of the synthetic approach for the production of biotinylated chemokines is that the position and the amount of biotin moieties introduced along the sequence are fully controlled. This is not the case for chemokines of recombinant origin, which are usually modified with activated biotin forms. As a result, the chemokines are indiscriminately derivatized, for instance, by biotinylation of their amino groups. A commercially available biotinylated chemokine of recombinant origin was analyzed in our laboratory. It was found to be constituted of multiple chemokine species, likely corresponding to molecules biotinylated to various extents. In addition, this material was found to be of reduced biological activity (unpublished results). This situation was likely due to modifications of the N-terminal residue and lysine residues in the N-terminal region of the chemokine needed for binding to its receptor. Indeed, this is a limitation that was previously reported in the literature. 9 Moreover, modifications of chemokines during stepwise synthesis are not restricted to biotin but open the possibility for using other haptens (e.g., dinitrophenol, digoxin) and unnatural amino acids. Biotinylated chemokines offer end users flexibility in terms of choice among detection reagents (e.g., FITC-avidin and Alexa Fluor-avidin). However, for high-throughput applications, such as the screening of large libraries of chemical compounds, a one-step binding assay would be advantageous. In this respect, this study showed that cell staining was feasible with preformed complexes between biotinylated CCL22(K66) and FITCavidin. Thus, staining can be achieved in a one-step procedure, even though one may argue that the pharmacological features of chemokine and avidin complexes might differ from the ones of monovalent chemokines. These considerations would indicate that chemokines directly labeled with fluorescent dyes would be ideal in terms of ease of use and pharmacological features. This approach is currently pursued in our laboratory, and preliminary results have established the feasibility of this approach (manuscript in preparation).
The results presented in this report validated the use of synthetic biotinylated chemokines for the development of nonradioactive whole-cell binding assays, provided the positions along the sequence where the biotin moieties are introduced are carefully evaluated. The combination, in the same assay, of biotinylated synthetic chemokines and chemokine receptor-transfected B cells, such as those used in the present study, resulted in a robust nonradioactive whole-cell binding assay. Future work is aimed at evaluating whether this FACS-based assay can be transposed to other applications with higher throughput.
